In this randomized, open study, we compared the incidence of lower limb motor block associated with epidural labour analgesia provided by parturient-controlled method (PCEA) with continuous infusion (CIEA) using 0.2% ropivacaine. The PCEA group (n=20) received a demand-only regimen (bolus 5 ml, lockout 15 minutes). The rate of infusion of the CIEA group (n=20) was 8 ml/h. We found that pain relief was not significantly different between the two groups, although the PCEA group had a higher satisfaction score (P<0.05). Fewer parturients in the PCEA group had lower limb motor block (6 vs 14, P<0.05) . The total volume of ropivacaine used per hour was also lower in the PCEA group (median 8.75 vs 10.5 ml, P<0.05). No difference in the maternal or fetal outcome was detected. We conclude that PCEA with ropivacaine is an effective mode of analgesia which is dose-sparing and produces less motor block in comparison with CIEA.
Ropivacaine is an amide local anaesthetic agent which, compared with bupivacaine, has a lower potential for causing cardiotoxicity and a greater selectivity for sensory fibres [1] [2] [3] . As such, ropivacaine has great promise in obstetric analgesia. Initial reports suggested that epidural analgesia using ropivacaine 0.25% (given as intermittent top-up or continuous infusion) did not reduce motor block in comparison with 0.25% bupivacaine in obstetric analgesia 4, 5 . It is possible that the expected advantage of reduced motor block was outweighed by the relatively high concentration of ropivacaine. In view of this, a lower concentration of ropivacaine (i.e. 0.2%) was used in the current study.
Parturient-controlled epidural analgesia (PCEA) has been shown to be a reliable method which allows for the vast inter-parturient variation of analgesic drug requirement. PCEA also has the further advantage of reducing local anaesthetic requirements in comparison with continuous infusion epidural analgesia (CIEA) 6, 7 . To date, there are no studies that compare ropivacaine delivered by continuous infusion with PCEA.
In our study, by employing PCEA (in comparison with CIEA) we were interested in studying the incidence of undesirable motor block while achieving titrated analgesia.
MATERIALS AND METHODS
This was a prospective, randomized controlled trial, approved by the Hospital Research Ethics Committee and comprising 40 primigravid parturients of ASA I status in established labour (at least one painful contraction in five minutes). All had given written, informed consent to epidural analgesia. The exclusion criteria were cervical dilatation of 6 cm or more, bodyweight of 100 kg or more, age of 45 years or more and the presence of medical problems (e.g. diabetes mellitus, hypertension, coagulopathy, neurological defects and systemic infection) or obstetric complications (e.g. prematurity, previous caesarean delivery, pre-eclampsia and multiple pregnancy).
After obtaining a baseline pain score (based on the 0-100 visual analog scale, 0=no pain and 100=worst pain imaginable) and systolic blood pressure (measured non-invasively on the left arm), intravenous preloading of 0.5l of Ringer's lactate solution was given to each parturient.
Epidural analgesia was then instituted in the right lateral position at the L2-3 or L3-4 level with a 17 gauge Weiss needle by using the "loss of resistance to air" technique (Perisafe, Becton Dickinson). The epidural catheter was inserted 3 cm into the epidural space and after negative aspiration for blood, a test dose of 3.5 ml 1.5% lignocaine was followed by an initial 10 ml of 0.2% ropivacaine (Naropin, Astra Pharmaceuticals) administered in 2 to 4 ml aliquots. During the first 30 minutes after the initial dose, the following parameters and categories were assessed: systolic blood pressure (every five minutes), pain scores (every 15 minutes), highest sensory block to cold (using ice, every 15 minutes), the maximum degree of motor block in the lower limbs at the end of 30 minutes on the modified Bromage scale (0=no impairment, 1=unable to raise extended leg but able to move knees and feet, 2=unable to raise extended leg as well as flex knees, able to move feet, 3=not able to flex ankle, feet or knees) and the presence of other side-effects (e.g. shivering, nausea and vomiting).
Fifteen minutes after the initial epidural dose, provided that analgesia was adequate (pain score of 30 or lower and bilateral sensory loss to cold at or higher than T10 but not more cephalad than T4) and the parturients were haemodynamically stable (a reduction of systolic blood pressure no greater than 20% of the baseline value, heart rate of 55 per minute or faster and the absence of symptoms such as giddiness and nausea), the parturients were randomized into two groups (by sealed envelope assignment), a PCEA group (study group) and a CIEA group (control group). The PCEA regimen was a demand bolus of 5 ml 0.2% ropivacaine without a background infusion; a lockout interval of 15 minutes and maximum hourly allowance of 15 ml (delivered by a Graseby 9300 PCA Pump). All the parturients in this group were clearly instructed on the concept and the operation of the PCEA pump, such as activation when contractions were felt (and not to wait until the pain became unbearable) by pressing the button once (this being accompanied by a "beep"). They were also informed that for reasons of safety, only one dose would be allowed every 15 minutes and further activation of the pump during this lock-out period would be ineffective. They were also reassured about the safety of activating the pump as often as necessary. Conversely, parturients in group B received continuous infusion epidural analgesia (CIEA) at the rate of 8 ml/h started 15 minutes after the initial dose, provided adequate analgesia and haemodynamic stability had been established.
If the pain score remained at 30 or higher 15 minutes after the initial dose of 10 ml 0.2% ropivacaine in either group, an additional epidural dose of 5 ml 0.2% ropivacaine was given. If pain relief was adequate (i.e. pain score less than 30), the study was continued in the manner as described above. If the pain score still remained at 30 or more after the next 15 minutes, the block was classified as a failure and the parturient excluded from the study.
The parturients in both groups were monitored two-hourly for systolic blood pressure, pain score, level of sensory block, degree of motor block, the total amount of local anaesthetic agent used and, in the case of the PCEA group, the proportion of successful attempts of activating the PCEA pump. Physician top-ups of 5 ml 0.2% ropivacaine (up to the maximum of 10 ml in an hour), were available if the painscore was 30 or more at the time of assessment or if the parturient complained of pain at any particular time during the duration of the study. If the systolic pressure fell by more than 20% of the baseline value, intravenous boluses of 5 mg ephedrine were given. In the presence of complete motor block and/or sensory block above the fourth thoracic dermatome (T4), the parturients were withdrawn from the study to exclude possible subdural or subarachnoid catheter placement.
Epidural analgesia was continued until delivery. An additional bolus dose of 50 µg of epidural fentanyl with the second rescue dose of 0.2% ropivacaine was given if the request for pain relief was made at the second stage of labour, and a total of 15 ml 0.2% ropivacaine was allowed at this stage. Additional data collected were the mode of delivery and the duration of second stage, neonatal birthweight and Apgar scores (1 and 5 minutes), overall satisfaction with analgesia (one hour post-delivery on a 0-100 scale, 0=very dissatisfed and 100=extremely satisfied), and sideeffects, namely hypotension (a reduction by 20% or more of the baseline systolic pressure), nausea (and vomiting) and shivering when epidural analgesia was in progress.
Fetal heart monitoring by cardiotocogram was continued throughout the study. The interpretation of tracings was performed by independent obstetricians who provided appropriate intervention if necessary. All the fetal cardiotocograms were confirmed to be normal prior to labour analgesia.
For demographic data (such as maternal age, weight and height, baseline systolic blood pressure and neonatal weight) the Student's t-test was used for statistical comparison between the two groups. For intergroup comparison of cervical dilatation at the time of epidural administration, pain scores, satisfaction scores, volume of local anaesthetics used, the duration of epidural analgesia as well as the second stage of labour and the highest sensory block achieved, the Wilcoxon rank sum test was used. For comparison of proportion of parturients in the two groups, χ 2 test (the use of oxytocin, shivering and motor block) and Fisher's exact test (nausea and hypotension) were used. The sample size was computed to detect (with the power of 0.8 and P value <0.05) a reduction of 25% in the occurrence of lower limb motor blockade in the PCEA group in comparison with the CIEA group.
RESULTS
Both groups were similar in terms of demographic data, baseline systolic blood pressure, cervical dilatation, pain scores and the use of oxytocin before epidural analgesia (Table 1) .
Parturients in both groups had similar pain scores at 2 hours, 4 hours, 6 hours and after 6 hours from the initiation of epidural analgesia (but before the onset of the second stage of labour). The median pain score for PCEA group ranged from 0 to 10 and that of the CIEA group from 0 to 13.5 (P>0.05) ( Figure 1 ).
Three parturients in the PCEA group and two in the CIEA group required an additional dose at the start of the study. There was one failure in each group, these being excluded from the study. The over-all satisfaction score was higher in the PCEA group (P<0.05), with a median of 90 (range 65-98) versus 80 (60-85) in the CIEA group. The median value of the percentage of successful demands over the total number of demands for analgesia made for each parturient in the PCEA group was 74% (range 45% to 100%).
The total volume of 0.2% ropivacaine used per hour of labour was significantly lower in PCEA group (median 8.75 vs 10.5 ml, P<0.05). Four parturients in CIEA group (three of the parturients had one top-up each at the second, fourth and sixth hours while the last one had two top-ups, at the fourth and sixth hours) required at least one physician epidural top-up during the study before the second stage of labour. This compared with three in PCEA group (two of the parturients had one top-up each at the fourth and the eighth hours, while the last one had two top-ups at the fourth and the sixth hours) (P>0.05). Three parturients in each group required analgesia during the second stage of labour.
There was no significant difference between the two groups in the duration of labour after epidural analgesia or in the duration of second stage of labour. The CIEA group was associated with twice the number of abnormal fetal heart tracings leading to operative delivery (n=4) compared with PCEA group (n=2) but this was not significant (P>0.05). There was no significant difference in the neonatal birthweight between the two groups (PCEA mean 3.2 kg, SD 0.3, versus CIEA 3.3 kg, SD 0.2, P>0.05). There was no difference in the Apgar scores between the two groups, with 19 and 18 of the neonates registering a score of 7 or greater at the first minute of birth in the PCEA and CIEA groups respectively (P>0.05). The Apgar score was more than 7 in all the neonates 5 minutes after birth ( induction of analgesia, the CIEA group had a higher proportion of parturients with lower limb motor block (i.e. Bromage score 1 or above, P<0.05) (Figure 2 ). There was no significant difference in other side-effects ( Table 3 ). The PCEA group had a total of 6/20 parturients with Bromage score >0 versus 14/20 in the CIEA group (P<0.05). There were no accidents resulting from human error or mechanical malfunction of the PCEA pump.
DISCUSSION
In this study, 0.2% ropivacaine delivered by the PCEA approach reduced the total local anaesthetic requirement and improved lower limb mobility in comparison with CIEA. In spite of the fact that the efficacy of pain relief was the same, maternal satisfaction was greater in the PCEA group. We attributed this in part to the autonomy of the parturients in the PCEA group to determine the degree of pain relief, as well as their reduced motor block of the lower limbs.
Benhamou et al suggested that 8 ml/hr of 0.2% ropivacaine was a desirable rate for CIEA, because at 4 ml/h there was a trend towards inferior analgesia as shown by additional bolus requirements while at 10 ml/h local anaesthetic consumption was higher and increased motor block was detected 8 . However, our results showed that 8 ml/h was still associated with a high incidence of lower limb motor block, as assessed by the modified Bromage score. We had chosen the modified Bromage system because of its simplicity and its usefulness in detecting gross, clinically significant differences with respect to motor block. On the other hand, our study provided evidence that in comparison with CIEA (8 ml/h), analgesia from a PCEA method could reduce the incidence of lower limb motor impairment, possibly by allowing the individualization of care and therefore ensuring that the optimum amount of local anaesthetic agent is delivered. Despite a similar demographic profile, duration of labour and efficacy of pain relief, the hourly requirement for local anaesthetic agent during labour was significantly lower in the PCEA group. However, neither the reduced amount of ropivacaine used nor the lower degree of motor block in the PCEA group in our study affected the overall mode of delivery profile or the fetal outcome.
We used the readily prepared 0.2% ropivacaine from a 200 ml Polybag ® (Astra Pharmaceuticals) to reduce the potential of breaching sterility from manoeuvres such as the dilution of drugs at the bedside. It remains to be seen whether a further reduction in the concentration of ropivacaine via the PCEA route might have any further impact on the degree of lower limb motor block. A recent investigation of PCEA showed that, despite having a lower concentration of 0.125% ropivacaine, the incidence of lower limb motor block can still be as high as 75%. In that study, however, in addition to a relatively large initial test dose, a high background infusion rate of 6 ml/h was also used 9 . The advantage of a background infusion in comparison with the demand-only mode is debatable, as there is conflicting evidence regarding the benefits of a fixed-rate background infusion. At least one study has demonstrated that while no analgesic advantage is derived from the continuous infusion, it can be associated with excessive cephalad spread of sensor block 10 . Our main objective in using the demand only mode of PCEA was to enable the maximum flexibility of self-titrated analgesia. Previously, various PCEA regimens have been used. Gambling and co-workers did not find any significant difference among a range of combinations of bolus size and lock-out time 6 . Nevertheless, we deemed that an adequate demand volume was important. Christiaens et al have recently shown that a bolus of 4 ml of 0.5% bupivacaine was ineffective in providing labour analgesia compared with a higher volume of the same amount of local anaesthetic 11 . We consider FIGURE 2: The number of parturients and the maximum degree of lower limb motor block at various intervals of assessment during epidural analgesia. 0H (hour) denotes the maximum degree of motor block 30 minutes after induction of analgesia. PC=PCEA gp, CI=CIEA gp. our current PCEA regimen proved a viable option for labour pain relief because of the relatively high ratio of successful to total PCEA demands and the relatively lower percentage of parturients (15%) who required at least one physician top-up during the study.
In conclusion, our study found that when using 0.2% ropivacaine as the sole agent, our current PCEA approach was as effective as CIEA. In some aspects, such as a reduction of local anaesthetic requirement, a lower degree of motor block and a greater maternal satisfaction score with regard to pain relief, it proved superior to a continuous epidural infusion of 8 ml/h of 0.2% ropivacaine for labour analgesia. Further studies are needed to determine the most suitable approach to PCEA with ropivacaine during labour.
